-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Boya Bio-Bio released the "Announcement on the Completion of the Share Agreement Transfer and the Completion of the Issuance of Shares to Specific Objects and the Change of Controlling Shareholders and Actual Controllers
.
" The announcement shows that on November 17, the company has received the "Confirmation of Acceptance of Share Registration Application" issued by the Shenzhen Branch of China Clearing Corporation.
The 78,308,575 A-share ordinary shares issued by the company to China Resources Pharmaceutical Holdings have been registered.
The company has now registered with the Shenzhen Stock Exchange.
Apply for the listing of new shares
.
After the completion of the share agreement transfer and the issuance of shares to specific targets, China Resources Pharmaceutical Holdings became its controlling shareholder, China Resources Co.
, Ltd.
became its actual controller, and the State-owned Assets Supervision and Administration Commission of the State Council became its ultimate actual controller
.
Public information shows that on September 28, 2020, China Resources Pharmaceutical has issued an announcement stating that it intends to acquire no less than 16% of Boya Biotech held by Gaotejia Group, and entrusts the voting rights of the remaining shares of the company held by Gaotejia Group
.
After the transaction is completed, China Resources Pharmaceuticals will become the controlling shareholder of Boya Biology
.
In addition, on July 15, 2021, Boya Biopharmaceuticals issued an announcement stating that the controlling shareholder Gao Tejia Group transferred 69,331,978 shares (accounting for 16% of Boya Biotech’s total share capital) to China Resources Pharmaceutical through an agreement transfer.
It is a holding company and announced that it has completed the transfer and registration procedures at the Shenzhen Branch of China Clearing Corporation
.
Industry analysts believe that entering Liberal Arts will not only benefit Liberal Arts, but for China Resources Pharmaceuticals, it will also be an important move to perfect the puzzle and make up for shortcomings
.
It is understood that Boya Bio is mainly engaged in the research and development, production and sales of blood products.
The main products are albumin, immunoglobulin and coagulation factors
.
At present, Boya Biology is one of the nationally perfect manufacturers of albumin and intravenous human immunoglobulin, and it is also one of the few enterprises in the country with complete products of the three categories
.
China Resources Pharmaceuticals owns China Resources Pharmaceutical Commercial, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Donge Ejiao, China Resources Zizhu, China Resources Biology, China Pharmaceutical Research and Development Center and other enterprises
.
Although the business is extensive, in the blood products field, due to the high industry barriers, it is not yet competitive
.
Therefore, under the background that the domestic blood product industry will continue to maintain steady growth in the future, China Resources Pharmaceuticals has only begun to accelerate its deployment in the blood product market through acquisitions
.
It is reported that in 2018 before entering Boya Biotech, China Resources Pharmaceuticals had negotiated strategic cooperation with blood products manufacturer Jet Belling
.
In addition to CR Pharmaceutical's optimistic view on the future cooperation and development of the two parties, Boya Biotech also made it clear that this equity change will help the listed company to optimize the equity structure, promote the iterative upgrade of its main business, and enhance the long-term profitability of the listed company.
Shareholders share the dividends brought about by corporate development and promote the sustainable development of listed companies
.
The industry predicts that in the future, driven by favorable policies and external mergers and acquisitions, the blood product market will continue to expand, and its investment value will also increase simultaneously.
Will usher in further development
.
.
" The announcement shows that on November 17, the company has received the "Confirmation of Acceptance of Share Registration Application" issued by the Shenzhen Branch of China Clearing Corporation.
The 78,308,575 A-share ordinary shares issued by the company to China Resources Pharmaceutical Holdings have been registered.
The company has now registered with the Shenzhen Stock Exchange.
Apply for the listing of new shares
.
After the completion of the share agreement transfer and the issuance of shares to specific targets, China Resources Pharmaceutical Holdings became its controlling shareholder, China Resources Co.
, Ltd.
became its actual controller, and the State-owned Assets Supervision and Administration Commission of the State Council became its ultimate actual controller
.
Public information shows that on September 28, 2020, China Resources Pharmaceutical has issued an announcement stating that it intends to acquire no less than 16% of Boya Biotech held by Gaotejia Group, and entrusts the voting rights of the remaining shares of the company held by Gaotejia Group
.
After the transaction is completed, China Resources Pharmaceuticals will become the controlling shareholder of Boya Biology
.
In addition, on July 15, 2021, Boya Biopharmaceuticals issued an announcement stating that the controlling shareholder Gao Tejia Group transferred 69,331,978 shares (accounting for 16% of Boya Biotech’s total share capital) to China Resources Pharmaceutical through an agreement transfer.
It is a holding company and announced that it has completed the transfer and registration procedures at the Shenzhen Branch of China Clearing Corporation
.
Industry analysts believe that entering Liberal Arts will not only benefit Liberal Arts, but for China Resources Pharmaceuticals, it will also be an important move to perfect the puzzle and make up for shortcomings
.
It is understood that Boya Bio is mainly engaged in the research and development, production and sales of blood products.
The main products are albumin, immunoglobulin and coagulation factors
.
At present, Boya Biology is one of the nationally perfect manufacturers of albumin and intravenous human immunoglobulin, and it is also one of the few enterprises in the country with complete products of the three categories
.
China Resources Pharmaceuticals owns China Resources Pharmaceutical Commercial, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Donge Ejiao, China Resources Zizhu, China Resources Biology, China Pharmaceutical Research and Development Center and other enterprises
.
Although the business is extensive, in the blood products field, due to the high industry barriers, it is not yet competitive
.
Therefore, under the background that the domestic blood product industry will continue to maintain steady growth in the future, China Resources Pharmaceuticals has only begun to accelerate its deployment in the blood product market through acquisitions
.
It is reported that in 2018 before entering Boya Biotech, China Resources Pharmaceuticals had negotiated strategic cooperation with blood products manufacturer Jet Belling
.
In addition to CR Pharmaceutical's optimistic view on the future cooperation and development of the two parties, Boya Biotech also made it clear that this equity change will help the listed company to optimize the equity structure, promote the iterative upgrade of its main business, and enhance the long-term profitability of the listed company.
Shareholders share the dividends brought about by corporate development and promote the sustainable development of listed companies
.
The industry predicts that in the future, driven by favorable policies and external mergers and acquisitions, the blood product market will continue to expand, and its investment value will also increase simultaneously.
Will usher in further development
.
